Featured Research

from universities, journals, and other organizations

Chemical stem cell signature predicts treatment response for acute myeloid leukemia

Date:
February 3, 2014
Source:
Albert Einstein College of Medicine of Yeshiva University
Summary:
Researchers have found a chemical “signature” in blood-forming stem cells that predicts whether patients with acute myeloid leukemia (AML) will respond to chemotherapy.

Researchers at Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center have found a chemical "signature" in blood-forming stem cells that predicts whether patients with acute myeloid leukemia (AML) will respond to chemotherapy.

The findings are based on data from nearly 700 AML patients. If validated in clinical trials, the signature would help physicians better identify which AML patients would benefit from chemotherapy and which patients have a prognosis so grave that they may be candidates for more aggressive treatments such as bone-marrow transplantation. The paper was published today in the online edition of the Journal of Clinical Investigation.

Sparing Patients from Debilitating Side Effects

According to the American Cancer Society, AML accounts for nearly one-third of all new leukemia cases each year. In 2013, more than 10,000 patients died of AML.

"AML is a disease in which fewer than 30 percent of patients are cured," said co-senior author Ulrich Steidl, M.D., Ph.D., associate professor of cell biology and of medicine and the Diane and Arthur B. Belfer Faculty Scholar in Cancer Research at Einstein and associate chair for translational research in oncology at Montefiore. "Ideally, we would like to increase that cure rate. But in the meantime, it would help if we could identify who won't benefit from standard treatment, so we can spare them the debilitating effects of chemotherapy and get them into clinical trials for experimental therapies that might be more effective."

Analyzing Methylation Patterns

The Einstein study focused on so-called epigenetic "marks" -- chemical changes in DNA that turn genes on or off. The researchers focused on one common epigenetic process known as methylation, in which methyl (CH3) groups attach in various patterns to the genes of human cells. Researchers have known that aberrations in the methylation of hematopoietic, or blood-forming, stem cells (HSCs) can prevent them from differentiating into mature blood cells, leading to AML.

Dr. Steidl suspected that comparing how closely the DNA methylation patterns in the cancerous white blood cells of AML patients resembled the patterns found in healthy individuals' HSCs might foretell the patients' response to treatment. To find out, he and his colleagues at the Albert Einstein Cancer Center carried out a novel DNA methylation analysis on 561 genes in healthy HSCs at various stages of differentiation. This new technique, developed by co-senior author Amit Verma, M.D., allows researchers, for the first time, to study DNA methylation of cells such as HSCs that can be found only in small quantities. Dr. Verma is associate professor of medicine and of developmental & molecular biology at Einstein and director, hematologic malignancies at the Montefiore Einstein Center for Cancer Care.

The researchers first analyzed HSCs from three healthy individuals to determine normal methylation patterns. They found that in the HSCs of healthy people, most DNA cytosines (one of four main components of DNA) are methylated. They noted that where demethylation (removal of methyl groups) occurs, it's limited mainly to one particular stage of HSC differentiation.

Using Epigenetic Signatures to Predict Survival

The researchers hypothesized that by comparing the "epigenetic signature" of healthy people's HSCs with that of AML patients' cancerous white blood cells, they could predict survival of AML patients. In other words, patients with a methylation pattern resembling that of healthy people's HSCs (i.e., a "low score") would be more likely to live longer -- and therefore benefit more from chemotherapy -- than patients with a high score.

The researchers then tested their scoring method using data on 688 AML patients in three different clinical trials, In each of these groups, patients with low scores (methylation patterns similar to normal HSCs) had approximately twice the median survival time of patients with high scores. "Our epigenetic stem cell signature was clearly superior to similar tests that have been used," said Dr. Steidl.

Dr. Steidl and his colleagues are now studying the genes that are included in the aberrant signatures to determine if they play a role in causing AML.


Story Source:

The above story is based on materials provided by Albert Einstein College of Medicine of Yeshiva University. Note: Materials may be edited for content and length.


Journal Reference:

  1. Boris Bartholdy, Maximilian Christopeit, Britta Will, Yongkai Mo, Laura Barreyro, Yiting Yu, Tushar D. Bhagat, Ujunwa C. Okoye-Okafor, Tihomira I. Todorova, John M. Greally, Ross L. Levine, Ari Melnick, Amit Verma, Ulrich Steidl. HSC commitment–associated epigenetic signature is prognostic in acute myeloid leukemia. Journal of Clinical Investigation, 2014; DOI: 10.1172/JCI71264

Cite This Page:

Albert Einstein College of Medicine of Yeshiva University. "Chemical stem cell signature predicts treatment response for acute myeloid leukemia." ScienceDaily. ScienceDaily, 3 February 2014. <www.sciencedaily.com/releases/2014/02/140203122543.htm>.
Albert Einstein College of Medicine of Yeshiva University. (2014, February 3). Chemical stem cell signature predicts treatment response for acute myeloid leukemia. ScienceDaily. Retrieved August 1, 2014 from www.sciencedaily.com/releases/2014/02/140203122543.htm
Albert Einstein College of Medicine of Yeshiva University. "Chemical stem cell signature predicts treatment response for acute myeloid leukemia." ScienceDaily. www.sciencedaily.com/releases/2014/02/140203122543.htm (accessed August 1, 2014).

Share This




More Health & Medicine News

Friday, August 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

House Republicans Vote to Sue Obama Over Healthcare Law

House Republicans Vote to Sue Obama Over Healthcare Law

Reuters - US Online Video (July 31, 2014) The Republican-led House of Representatives votes to sue President Obama, accusing him of overstepping his executive authority in making changes to the Affordable Care Act. Mana Rabiee reports. Video provided by Reuters
Powered by NewsLook.com
Despite Health Questions, E-Cigs Are Beneficial: Study

Despite Health Questions, E-Cigs Are Beneficial: Study

Newsy (July 31, 2014) Citing 81 previous studies, new research out of London suggests the benefits of smoking e-cigarettes instead of regular ones outweighs the risks. Video provided by Newsy
Powered by NewsLook.com
Dangerous Bacteria Kills One in Florida

Dangerous Bacteria Kills One in Florida

AP (July 31, 2014) Sarasota County, Florida health officials have issued a warning against eating raw oysters and exposing open wounds to coastal and inland waters after a dangerous bacteria killed one person and made another sick. (July 31) Video provided by AP
Powered by NewsLook.com
Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins